Published in J Immunol on August 01, 1985
T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol (1987) 4.76
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med (2005) 3.80
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest (2001) 2.86
cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc Natl Acad Sci U S A (1990) 1.46
Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol (2008) 1.44
cAMP antagonizes interleukin 2-promoted T-cell cycle progression at a discrete point in early G1. Proc Natl Acad Sci U S A (1988) 1.30
In vitro and in vivo T cell responses in mice during bronchopulmonary infection with mucoid Pseudomonas aeruginosa. Clin Exp Immunol (1995) 1.26
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Prostaglandin E2 enhances and gamma interferon inhibits germ tube formation in Candida albicans. Infect Immun (1990) 1.17
Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol (2011) 1.12
Suppression of interleukin 2-dependent human T cell growth in vitro by prostaglandin E (PGE) and their precursor fatty acids. Evidence for a PGE-independent mechanism of inhibition by the fatty acids. J Clin Invest (1990) 1.05
Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest (1987) 1.04
Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology (1993) 0.98
The inhibition of T-lymphocyte proliferation by fatty acids is via an eicosanoid-independent mechanism. Immunology (1992) 0.95
Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2. J Exp Med (1987) 0.93
Regulation of T-cell proliferative responses by cells from solid lung tissue of M. tuberculosis-infected mice. Immunology (1991) 0.93
Immunosuppression by seminal prostaglandins. Clin Exp Immunol (1989) 0.92
Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa-susceptible and resistant mice following immunization with heat-killed bacteria. Clin Exp Immunol (2000) 0.91
Cholera toxin partially inhibits the T-cell response to phytohaemagglutinin through the ADP-ribosylation of a 45 kDa membrane protein. Biochem J (1988) 0.91
Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells. Br J Pharmacol (2000) 0.90
Vesicular Trans-Cell Wall Transport in Fungi: A Mechanism for the Delivery of Virulence-Associated Macromolecules? Lipid Insights (2008) 0.90
Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin Exp Immunol (2002) 0.90
Acquisition of cell-mediated immunity to Leishmania. I. Primary T-cell activation detected by IL-2 receptor expression. Immunology (1987) 0.89
Proinflammatory and immunoregulatory roles of eicosanoids in T cells. Front Immunol (2013) 0.87
Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol (2002) 0.86
Lipocortin-independent effect of dexamethasone on phospholipase activity in a thymic epithelial cell line. Biochem J (1989) 0.85
Dual signal transduction through delta opioid receptors in a transfected human T-cell line. Proc Natl Acad Sci U S A (1996) 0.84
GM-CSF increases the ability of cultured macrophages to support autologous CD4+ T-cell proliferation in response to Dermatophagoides pteronyssinus and PPD antigen. Immunology (1997) 0.83
Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂. Pharm Pat Anal (2013) 0.82
The expression of functional IL-2 receptor on activated macrophages depends on the stimulus applied. Immunology (1989) 0.82
Prostaglandin E2 selectively increases interferon gamma receptor expression on human CD8+ lymphocytes. J Clin Invest (1989) 0.81
Augmentation of antigen-specific lymphoproliferative responses in vitro by biological response modifiers. Clin Exp Immunol (1994) 0.81
Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response. Cancer Immunol Immunother (2009) 0.80
Cyclic AMP suppresses interleukin-5 synthesis by human helper T cells via the downregulation of the calcium mobilization pathway. Br J Pharmacol (1999) 0.79
Kallikrein stimulates arachidonic acid release and production of prostaglandins from TEA3A1 endocrine thymic epithelial cells. Biochem J (1989) 0.78
Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma. Immunology (1990) 0.77
Unsaturated fatty acids suppress interleukin-2 production and transferrin receptor expression by concanavalin A-stimulated rat Iymphocytes. Mediators Inflamm (1992) 0.76
Fatty acid-binding protein 4 (FABP4) and FABP5 modulate cytokine production in the mouse thymic epithelial cells. Histochem Cell Biol (2012) 0.76
Selective activation of functional suppressor cells by human seminal fluid. Clin Exp Immunol (1986) 0.75
Pycnogenol attenuates the symptoms of immune dysfunction through restoring a cellular antioxidant status in low micronutrient-induced immune deficient mice. Nutr Res Pract (2014) 0.75
Reversal of lipopolysaccharide-analog-induced antibody suppression by anti-transforming growth factor beta and indomethacin. Infect Immun (1995) 0.75
Characterization of ATP receptor responsible for the activation of phospholipase A2 and stimulation of prostaglandin E2 production in thymic epithelial cells. Biochem J (1995) 0.75
Antigen-presenting characteristics of peritoneal cells of Salmonella enteritidis 11RX-infected mice. Immunology (1992) 0.75
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Recognition by pregnancy serums of non-HL-A alloantigens selectively expressed on B lymphocytes. J Exp Med (1975) 4.96
Induction of tumor necrosis factor alpha expression in human T lymphocytes following ionizing gamma irradiation. J Interferon Cytokine Res (1996) 4.88
Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood (2000) 3.45
The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med (1991) 3.35
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci U S A (1985) 3.22
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Two HLA-linked loci controlling the fourth component of human complement. Proc Natl Acad Sci U S A (1978) 3.05
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med (1995) 2.85
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia (2009) 2.78
Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet (1978) 2.66
HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A (1984) 2.56
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood (2001) 2.52
The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest (1992) 2.51
Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med (1983) 2.45
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet (1985) 2.44
Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet (1973) 2.41
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect (2011) 2.38
Review of nocardial infections in France 1987 to 1990. Eur J Clin Microbiol Infect Dis (1992) 2.36
Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A (1986) 2.34
Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis (1996) 2.33
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis (1987) 2.18
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med (1987) 2.17
Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect (2004) 2.13
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 2.08
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br J Dermatol (1998) 2.08
Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol (1993) 2.06
Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis (1996) 2.02
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01
Nomenclature for factors of the HLA system, 1990. Tissue Antigens (1991) 1.98
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
Trichosporon on humans: a practical account. Mycoses (1994) 1.90
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci U S A (2001) 1.90
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A (1984) 1.89
A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants. J Immunol (1986) 1.88
Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med (1993) 1.86
Chido and Rodgers blood groups are distinct antigenic components of human complement C4. Nature (1978) 1.85
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis (2001) 1.84
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood (1992) 1.81
Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol (1993) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Mutations in the gene encoding neutrophil elastase (ELA2) are not sufficient to cause the phenotype of congenital neutropenia. Br J Haematol (2001) 1.78
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab (1983) 1.77
Hereditary C2 deficiency: Genetic studies and association with the HL-A system. J Exp Med (1975) 1.75
CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci U S A (1994) 1.70
Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet (1981) 1.70
Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J Immunol (2001) 1.69
Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med (1989) 1.67
Acute retinal necrosis in the course of AIDS: study of 26 cases. AIDS (1996) 1.66
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood (1997) 1.61
Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens (2003) 1.60
Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood (1986) 1.60
Two steroid 21-hydroxylase genes are located in the murine S region. Nature (1985) 1.58
Nomenclature for factors of the HLA system, 1991. WHO Nomenclature Committee for factors of the HLA system. Tissue Antigens (1992) 1.58
Nomenclature for factors of the HLA system, 2004. Tissue Antigens (2005) 1.57
Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex. N Engl J Med (1977) 1.55
Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood (2000) 1.54
Frequent deletion and duplication of the steroid 21-hydroxylase genes. Am J Hum Genet (1986) 1.54
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol (1984) 1.54
Novel isoforms of murine intercellular adhesion molecule-1 generated by alternative RNA splicing. J Immunol (1995) 1.53
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. J Antimicrob Chemother (1999) 1.52
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol (1984) 1.46
The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.46
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood (1992) 1.44
The mechanism of inhibition of human IL 2 production. J Immunol (1982) 1.44
HIV-associated non-Hodgkin's lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol (1991) 1.44
Interleukin-2 correction of defective in vitro T-cell mitogenesis in patients with common varied immunodeficiency. J Clin Immunol (1984) 1.44
Src-induced activation of inducible T cell kinase (ITK) requires phosphatidylinositol 3-kinase activity and the Pleckstrin homology domain of inducible T cell kinase. Proc Natl Acad Sci U S A (1997) 1.43
Comparison of one-dimensional IEF patterns for serologically detectable HLA-A and B allotypes. Immunogenetics (1984) 1.43
Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group. Clin Infect Dis (1996) 1.42
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer (1997) 1.41
Mixed lymphocyte culture determinants and C2 deficiency: LD-7a associated with C2 deficiency in four families. J Exp Med (1975) 1.40
Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene (2007) 1.40
Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci U S A (1988) 1.40
Nomenclature for factors of the HLA system, 1998. Tissue Antigens (1999) 1.40
Serum G-CSF levels are not increased in patients with antibody-induced neutropenia unless they are suffering from infectious diseases. Br J Haematol (1999) 1.39